Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

NCT ID: NCT01005797

Last Updated: 2017-03-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2017-01-31

Brief Summary

The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.

Conditions

Renal Cancer; Non Small Cell Lung Cancer (NSCLC); Soft Tissue Sarcoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Expansion A

Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Group Type: EXPERIMENTAL

Panobinostat (LBH589), Sorafenib

Intervention Type: DRUG

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Expansion B

Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Group Type: EXPERIMENTAL

Panobinostat (LBH589), Sorafenib

Intervention Type: DRUG

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Expansion C

Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.

Group Type: EXPERIMENTAL

Panobinostat (LBH589), Sorafenib

Intervention Type: DRUG

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Interventions

Panobinostat (LBH589), Sorafenib

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged ≥ 18 years old

2. ECOG Performance Status of ≤ 2

3. Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

4. Part A (dose escalation): Histologically or cytologically documented metastatic renal cell carcinoma (RCC) of all histologic types, soft tissue sarcoma (STS) limited to the following histologies: angiosarcoma, liposarcoma, and leiomyosarcoma, or non-squamous non-small-cell lung carcinoma (NSCLC). Parts B (RCC) and C (NSCLC) and D (STS)(expanded cohorts). Patients with RCC must have progressive metastatic disease and received at least one multi-kinase inhibitor (e.g., sorafenib/Nexavar or sunitinib/Sutent), or an mTOR inhibitor (e.g., Temsirolimus). Patients with STS must have progressive disease and have received at least two therapeutic regimens (first-line, second-line treatments).

For patients with metastatic NSCLC, they must have received two standard therapeutic regimens (first-line and second-line treatments).

In Part A, evaluable disease by radiology and/or a recognized serum tumor marker is required. In Parts B, C, and D measurable disease by RECIST is required

5. Predicted life expectancy ≥ 12 weeks

6. Patients may have had prior therapy, providing the following conditions are met:

Patients must have recovered from any treatment related toxicities (with the exception of alopecia) to ≤ CTC grade 1 (fatigue, and neurotoxicity at grade 2 are permissible if stable for >3 months) prior to registration.

1. Chemotherapy: A minimum of 5 predicted half-lives of the agent must have elapsed between the end of treatment and registration on to the study. When halflives are not available the principle of 2 weeks for once daily medications and 3 weeks for agents given less frequently will be adopted, but discussion with the principal investigator is recommended.

2. Radiation: Patients may have had prior radiation therapy that has not exceeded 25% of bone marrow reserve provided that they have recovered from the acute, toxic effects of radiotherapy prior to registration. A minimum of 7 days must have elapsed between the end of radiotherapy to non-target lesions and registration into the study (minimum of 28 days for target lesions).

3. Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration.

7. Patients must meet the following laboratory criteria:

• Hematology:
• Neutrophil count of >1500/mm3
• Platelet count of > 100,000/mm3L
• Hemoglobin ≥ 9 g/dL
• Biochemistry:
• AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement
• Serum bilirubin ≤ 1.5 x ULN
• Serum creatinine ≤ 2.0 x ULN or 24-hour creatinine clearance ≥ 50 ml/min
• Total serum calcium (corrected for serum albumin) or ionized calcium ≥ LLN
• Serum potassium ≥ LLN
• Serum sodium ≥ LLN
• Serum albumin ≥ LLN or 2.5 g/dl
• Patients with any elevated Alkaline Phosphatase due to bone metastasis can be enrolled

8. INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib/LBH589 and monitored at least weekly, or as defined by the local standard of care, until the INR is stable. LBH589 and sorafenib may elevate the INR in those on coumadin derivatives

9. Patients must be clinically euthyroid (patients may be on thyroid hormone replacement)'

10. Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional normal

11. Supportive therapy including bisphosphonates is permissible. Previous use of myeloid and erythroid growth factor support is permissible, but not within 2 weeks of commencement of study. Primary prophylactic use of myeloid and erythroid growth factors is not permitted within the study, but intervention or secondary prophylaxis is permitted if instituted following the documentation of ≥ grade 3 neutropenia or ≥ grade 2 anemia (hemoglobin)

12. Patient must be accessible for repeat dosing and follow-up

13. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment. and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administration

Exclusion Criteria

1. NSCLC of squamous histology.

2. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

3. Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment

4. Known or suspected allergy to sorafenib or LBH589

5. Impaired cardiac function including any one of the following:

• Screening ECG with a QTc > 450 msec prior to enrollment to the study
• Patients with congenital long QT syndrome
• History of sustained ventricular tachycardia
• Any history of ventricular fibrillation or torsades de pointes
• Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible.
• Patients with a myocardial infarction or unstable angina within 6 months of study entry
• Congestive heart failure (NY Heart Association class III or IV)
• Right bundle branch block and left anterior hemiblock (bifasicular block)

6. Uncontrolled hypertension

7. Concomitant use of drugs with a risk of causing torsades de pointes (See Appendix 1.-1)

8. Concomitant use of CYP3A4 inhibitors (See Appendix 1.-2)

9. Patients with unresolved diarrhea > CTCAE grade 1

10. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589

11. Other concurrent severe and/or uncontrolled medical conditions

12. Patients who have undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

13. Concomitant use of any anti-cancer therapy or radiation therapy

14. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months).

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589

15. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom

16. Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin

17. Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis C; baseline testing for HIV and hepatitis C is not required

18. Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent

19. Symptomatic brain metastases which are not stable, require steroids, or anti-epileptic medication.

20. Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.

21. Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.

22. Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.

23. Serious non-healing wound, ulcer, or bone fracture.

24. Use of St. John's Wort or rifampin (rifampicin).

25. Any condition that impairs patient's ability to swallow whole pills.

26. Active or uncontrolled infections, or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study.

27. Any other condition, which in the investigator's opinion, would compromise the safety of the patient or the feasibility of completing the study objectives through the use of this patient.

Note: Investigators must ensure that the patients enrolled in the study will be available for all study procedures, including dosing, toxicity assessment and follow up and have the ability to understand the requirements of the study and provide signed informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Medical University of South Carolina

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Harry Drabkin, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of South Carolina

Locations

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, United States

Countries

United States

Other Identifiers

CLBH589BUS16T

Identifier Type: -

Identifier Source: secondary_id

101273

Identifier Type: -

Identifier Source: org_study_id